Skip to main content
2025 Annual Convention & Scientific Sessions Main banner

Concurrent Session-Banyan 3

Prostate Cancer: Genetic Insights and Evidence-Based Treatment of Localized Disease

Thursday, October 9, 2025
8:00 AM - 8:30 AM East Coast USA Time
Location: Banyan 3
Disclosure(s):
Daniel Isaac, DO: No relevant disclosure to display
Jason R. Beckrow, DO, FACOI, FAAHPM, HMDC: No financial relationships to disclose
Seer.cancer.gov​

Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, Kaochar S. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022 Apr 10;531:71-82. doi: 10.1016/j.canlet.2022.01.028. Epub 2022 Feb 3. PMID: 35122875; PMCID: PMC9701576.​

NCCN Prostate cancer guidelines Version 2.2026, 9/15/2025. www.nccn.org​

Pritcard C, Mateo J, Walsh M, De Sarkar N, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Eng J Med. 2016; 375:443-453.​

Akbari MR, Wallis CJ, Toi A, Trachtenberg J, Sun P, Narod SA, Nam RK. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer. 2014 Sep 9;111(6):1238-40. doi: 10.1038/bjc.2014.428. Epub 2014 Aug 7. PMID: 25101567; PMCID: PMC4453856.​

DeBono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castrate-resistant prostate cancer. N. Eng J Med. 2020;382:2091-2102​

Hamdy F, Donovan J, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-1558​

Learning Objectives:

  • Understand the genetic risk factors for prostate cancer
  • Understand guideline driven recommendations for germline genetic testing in patients with prostate cancer.
  • Understand current treatment options for men with localized prostate cancer.